Who are Drug: Dose -SM-88's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Trimetazidine mimic, Trimetazidine hydrochloride.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/drug-dose-sm-88.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Drug: Dose -SM-88 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Drug: Dose -SM-88 (Drug: Dose -SM-88) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Metabolic modulator. Area: Oncology.

phase 3 Metabolic modulator Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Drug: Dose -SM-88 (Drug: Dose -SM-88) — Pancreatic Cancer Action Network. SM-88 is a metabolic modulator that inhibits cancer cell metabolism by targeting key enzymes involved in glucose and amino acid utilization.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Drug: Dose -SM-88 TARGET	Drug: Dose -SM-88	Pancreatic Cancer Action Network	phase 3	Metabolic modulator
Trimetazidine mimic	Trimetazidine mimic	Shenyang Northern Hospital	marketed	Metabolic modulator; fatty acid oxidation inhibitor	LC3KAT (long-chain 3-ketoacyl-CoA thiolase)
Trimetazidine hydrochloride	Trimetazidine hydrochloride	The First Affiliated Hospital of Zhengzhou University	phase 3	Metabolic modulator	3-Ketoacyl CoA thiolase (3-KAT)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Metabolic modulator class)

Pancreatic Cancer Action Network · 1 drug in this class
The First Affiliated Hospital of Zhengzhou University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Drug: Dose -SM-88 — Competitive Intelligence Brief. https://druglandscape.com/ci/drug-dose-sm-88. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab